Elraglusib (9-ING-41)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Key Facts
About Actuate Therapeutics
Actuate Therapeutics is a micro-cap, clinical-stage biotech focused on developing elraglusib, a selective GSK-3β inhibitor, for difficult-to-treat cancers. Its strategy leverages a dual mechanism of action—direct tumor cytotoxicity and immune modulation—to enhance the efficacy of chemotherapy and immunotherapy. The company has advanced elraglusib into multiple Phase 2 trials in pancreatic cancer, salivary gland carcinoma, and hematologic malignancies, positioning it as a high-risk, high-reward investment tied to clinical data readouts.
View full company profileAbout Actuate Therapeutics
Actuate Therapeutics is a micro-cap, clinical-stage biotech focused on developing elraglusib, a selective GSK-3β inhibitor, for difficult-to-treat cancers. Its strategy leverages a dual mechanism of action—direct tumor cytotoxicity and immune modulation—to enhance the efficacy of chemotherapy and immunotherapy. The company has advanced elraglusib into multiple Phase 2 trials in pancreatic cancer, salivary gland carcinoma, and hematologic malignancies, positioning it as a high-risk, high-reward investment tied to clinical data readouts.
View full company profileAbout Actuate Therapeutics
Actuate Therapeutics is a micro-cap, clinical-stage biotech focused on developing elraglusib, a selective GSK-3β inhibitor, for difficult-to-treat cancers. Its strategy leverages a dual mechanism of action—direct tumor cytotoxicity and immune modulation—to enhance the efficacy of chemotherapy and immunotherapy. The company has advanced elraglusib into multiple Phase 2 trials in pancreatic cancer, salivary gland carcinoma, and hematologic malignancies, positioning it as a high-risk, high-reward investment tied to clinical data readouts.
View full company profile